Unravelling mitochondrial succinate transport during I/R and devising a novel transport inhibitor show promise for targeting I/R injury, but will efficacy remain under more human-like conditions present during I/R?

Cardiovascular Research

17 March 2026
Organised by: Logo
ESC Journals CARDIOVASCULAR PHARMACOLOGY CORONARY ARTERY DISEASE, ACUTE CORONARY SYNDROMES, ACUTE CARDIAC CARE Acute Cardiac Care Acute Coronary Syndromes BASIC SCIENCE

Contributors

ESC 365 is supported by